# Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma

> **NCT04934579** · PHASE2 · COMPLETED · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 17 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT04934579
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-01
- **Primary completion:** 2022-10-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04934579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04934579, "Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04934579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*